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studied and to normal kininogenase activity in all but one. 
The clinical manifestations completely disappeared in 6 pa-
tients and improved in 7 after the withdrawal of oestrogen. 
 Conclusion: Patients display extensive cleavage of HK in the 
plasma, which supports that AO precipitated by oestrogen 
contraception is BK-mediated. Recurrent urticaria may have 
been underestimated in this context. The presence of recur-
rent urticaria should not systematically rule out the diagno-
sis of BK-AO when the history is suggestive. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Angio-oedema (AO) refers to sudden and localized 
swelling in the subcutaneous and/or submucosal tissues 
 [1] . AO is usually white or pale pink and soft. It resolves 
without sequelae within a few hours or days. Some cases 
have an unrecognized cause and pathophysiology but 
most are classified as either histamine-mediated AO or 
bradykinin-mediated AO (BK-AO)  [2] ; the former often 
occurs rapidly, is typically associated with urticaria and 
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 Abstract 
 Background: Hereditary C1-inhibitor (C1-Inh) deficiency is 
associated with ‘bradykinin-mediated angio-oedema’ (BK-
AO) and is believed not to be associated with urticaria. Ac-
quired AO has been related to oestrogen contraceptives. 
 Objective: To demonstrate that AO precipitated by oestro-
gens and characterized by nonfunctional C1-Inh is mediated 
by BK and to evaluate the occurrence of urticaria in these 
patients.  Methods: A retrospective evaluation of patients re-
ferred for AO related to oestrogen was undertaken. Circulat-
ing C1-Inh, high molecular weight kininogen (HK) and en-
zymes involved in the metabolism of bradykinin were inves-
tigated.  Results: Fifteen patients were included. HK cleavage 
concurrent to oestrogen intake was demonstrated in 10 pa-
tients with available plasma. Eight patients reported recur-
rent or chronic urticaria. Discontinuation of the contracep-
tive resulted in a return to native C1-Inh and HK in all cases 
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less frequently with other symptoms of anaphylaxis, such 
as bronchospasm or shock. The most frequent known 
cause is hypersensitivity to a drug, insect venom, food or 
latex. BK-AO is characterized by episodes of recurrent 
AO of the extremities, genitalia, abdominal wall, tongue 
and/or larynx  [3] . The digestive tract is also frequently 
affected, and this suggestive involvement may cause se-
vere abdominal pain as well as transient ascites. BK-AO 
typically develops gradually, ranging from 24 h to 9 days. 
The demonstration of the mediation by BK has been con-
vincingly performed only in exemplary situations, due to 
the difficulties of measuring BK  [3] . Classically, BK-AO is 
not associated with urticaria. It does not respond (or 
poorly) to the usual treatment for histamine-mediated 
AO, i.e. antihistamines and steroids – and if it does, the 
response is significantly delayed  [3] .
 The best known types of BK-AO are associated with a 
severe functional deficiency of C1-inhibitor (C1-Inh), the 
serpin that controls the proteases of the classic comple-
ment pathway convertase and of the contact system that 
generates BK from high molecular weight kininogen 
(HK)  [4] . In such patients, C1-Inh activity is usually less 
than 30% of standard values. The hereditary deficiency is 
caused by a monoallelic mutation in the  SERPING1 gene 
which is responsible for the impaired synthesis and/or 
secretion of C1-Inh (resulting in low plasma antigen lev-
els) in type I, or for a dysfunctional reactive loop in C1-
Inh (but normal secretion) in type II  [5, 6] . BK-AO can 
also be acquired, either by the production of antibodies 
binding to C1-Inh or C1q in the context of B lymphopro-
liferative disease with gammopathy and/or autoimmune 
disease, or by uncontrolled proteolysis able to destroy C1-
Inh (directly or indirectly) in a tumoral setting  [7–9] .
 Iatrogenic BK-AO is increasingly encountered. It is 
mainly related to angiotensin-I-converting enzyme an-
tagonists, neutral endopeptidase inhibitors, angiotensin-
II receptor antagonists (sartans) or dipeptidylpeptidase 
IV inhibitors (gliptins). More recently, cases of AO have 
been reported associated with mild functional C1-Inh 
deficiency when using oestrogen contraceptives. Bouillet 
et al.  [10]  described 5 female patients who developed re-
current AO after starting oestroprogestative contracep-
tives. This AO was associated with a slightly lowered C1-
Inh function (activity greater than 50% of normal value) 
and normal serum C4 antigen levels. Functional defi-
ciency was associated with C1-Inh cleavage on immu-
noblotting and the presence of a 95-kD molecular spe-
cies. In most cases, AO resolved completely when contra-
ception was withdrawn. C1-Inh functional deficiency 
and electrophoretic abnormality were reversible after the 
causal contraceptive was discontinued. André et al.  [11] 
 also reported a female population receiving oral contra-
ceptives suffering from AO and/or urticaria with a mod-
erate deficiency of C1-Inh function. Discontinuation of 
oral contraception led to the resolution or improvement 
of the symptoms in 20 of the 22 patients.
 Finally, there is a type of inherited BK-AO with normal 
 SERPING1 gene. It is referred to as AO type III. Only 
women were affected in the first 10 families described by 
Bork et al.  [12]  and the occurrence of AO was strikingly 
correlated with oral contraception or pregnancy. Of these 
36 women, 14 were evaluated further and were found to 
have normal C1-Inh antigen levels and function. In all in-
dividuals, AO was clinically indistinguishable from he-
reditary AO types I or II. Binkley and Davis  [13]  later re-
ported another family with the same phenotype and ruled 
out any association with the  SERPING1 gene or with the 
promoter of F12 , the gene encoding factor XII. We dem-
onstrated autosomal dominant transmission of this type 
of hereditary AO in a large family in which men were ob-
ligate carriers  [14] , and finally reported the occurrence of 
the c.983C→A (p.Thr309Lys) missense mutation in the  F12 
 gene in this French family and in 3 German families. 
p.Thr309Lys is a gain-of-function mutation that markedly 
increases FXII activity without altering its plasma levels 
 [15] . Only a small subpopulation of these cases of inher-
ited AO type III was found to have missense mutations in 
the  F12 gene-encoding coagulation factor XII  [15, 16] . 
Therefore, inherited AO type III is probably genetically, 
and possibly pathophysiologically, heterogeneous.
 Classically, BK-AO and urticaria do not coexist and 
diagnosis of BK-AO should be excluded if urticaria is 
present. However, this has not been our experience over 
the past years with patients referred to CREAK (the 
French National Reference Centre of Kinin-Mediated 
Angio-Oedemas) who are suffering from BK-AO with no 
defects in the  SERPING1 gene. In the preliminary study 
reported here we therefore aimed to demonstrate that AO 
developed by female patients following the intake of oes-
trogenic contraceptives, a biologically well-characterized 
subpopulation with AO unrelated to  SERPING1 , was in-
deed mediated by BK, and we assessed the frequency of 
urticaria in this condition.
 Patients and Methods 
 Patients 
 We retrospectively reviewed the records of women referred to 
our centre between January 2007 and March 2010 with a clinical 
history suggestive of AO attributed to oestrogen contraceptives. 
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The inclusion criteria were:  (1) A clinical history of AO upon use 
of oestrogen contraceptive(s), with a poor response to antihista-
mines, even when given at a high dosage.  (2) Evidence of func-
tional deficiency of C1-Inh with residual activity  1 50%.  (3) Evi-
dence of C1-Inh protein cleavage on immunoblotting ( fig.  1 ). 
 (4) Correction of both biological abnormalities 3 months after 
discontinuation of the causal contraceptive. 
 We excluded female patients with inherited BK-AO types I and 
II worsened by oestrogen exposure. For each patient, a careful 
standardized telephone interview requested:  (1) A clinical history 
of AO: date of onset, frequency of attacks, trigger factors and lo-
cations (including digestive tract involvement).  (2) A potential 
clinical history of urticaria defined by the presence of mobile, 
transient, and pruriginous erythematous papules and plaques 
(wheals), including frequency, location, trigger factors, a chrono-
logical association with AO (or not) and duration. Acute urticar-
ia was defined as 1–4 isolated episodes, recurrent urticaria (RU) 
as  1 5 episodes and chronic urticaria (CU) as daily episodes. 
 (3) The name(s) of the contraceptive(s) and date(s) of initiation. 
 (4) The type of contraceptive prescribed at discontinuation of the 
trigger and the development of AO and urticaria. 
 Photographs of skin lesions were requested when available.
 Fifty-nine healthy female blood donors on oestrogen contra-
ceptives, aged 18–49 years old, were enrolled to establish the ref-
erence intervals for all biological parameters and were questioned 
about their medical history.
 Biological Analyses 
 C1-Inh antigen levels and C1-Inh function were assayed as de-
scribed by Drouet et al.  [17] . Briefly, C1-Inh function was mea-
sured on the basis of the residual esterase activity of plasma sam-
ples after incubation with C1s protease. In order to detect any 
possible serpin breakdown, calculation of C1-Inh specific func-
tion (U/mg) was based on the C1-Inh antigen level. Anti-C1-Inh 
immunoblots (The Binding Site, Saint Egrève, France) were per-
formed in nonreducing conditions on native samples or were sub-
mitted to incubation with C1s protease as previously described 
 [16] . Plasma kininogenase (amidase) activity before and after con-
traceptive discontinuation was measured using the Pro-Phe-Arg-
 p NA peptide substrate, representative of the 387–389 residue
sequence of HK  [16] . The anti-HK immunoblot analysis was
performed in nonreducing conditions on plasma samples with 
anti-human HK L-chain horseradish-conjugated sheep antibody 
(Enzyme Research, Cardiff, UK) and stained by ECL  (Amer-
sham, Courtaboeuf, France). Proteins were electrotransferred on 
Hybond  with prestained molecular weight markers. Plasma ac-
tivity of the kininases (aminopeptidase P, carboxypeptidase N 
and angiotensin-I-converting enzyme) were assessed according 
to Adam et al.  [18] , Cyr et al.  [19] and the protocol of the manu-
facturer (Bühlman, Mulhouse, France), respectively. Informed 
written consent for mutation analysis was obtained. Genomic 
DNA was isolated using a guanidine method. The  F12 gene was 
sequenced as previously described  [15] .
 Results 
 Patients 
 Fifteen female patients were included, corresponding 
to 17% of the population suffering from BK-AO followed 
in our centre. The most frequent causal contraceptives 
were: Diane  (ethinyloestradiol 35   g and cyproterone 
acetate 2 mg; n = 4) and Trinordiol  and Adepal  (ethi-
nyloestradiol 30–40   g and levonorgestrel 0.15–0.20 mg; 
n = 6). Only 1 case was reported for each of the following 
contraceptives: Melodia  (ethinyloestradiol 15   g and 
gestodene 0.06 mg), Moneva  (ethinyloestradiol 30   g 
and gestodene 0.075 mg), Efezial  (ethinyloestradiol
20   g and gestodene 0.075 mg), Jasmine  (ethinyloestra-
diol 30   g and drospirenone 3 mg) and the Evra  trans-
dermal contraceptive patch (ethinyloestradiol 600   g 
and norelgestromin 6 mg).
HK
(% cleavage)
Sample ID patient patientcontrol control
+ –
130 kDa
95 kDa
Anti-HK immunoblot Anti-C1-Inh immunoblot Mr
Plasma
activation
na act plasma  pl + C1s plasma  pl + C1s plasma  pl + C1s
Oestrogen
intake
+ –
100 85
 Fig. 1. Plasma samples from patient No. 12. Immunoblotting was 
performed using HRP-conjugated anti-C1-Inh and anti-HK L-
chain antibodies. During oestrogen intake (indicated as +) the 
presence of a cleaved, nonfunctional, 95 kDa species of C1-Inh 
was demonstrated. Controls for anti-HK immunoblot are nonac-
tivated (na) and dextran-sulphate activated (act) normal plasma 
samples. After withdrawal of the contraceptive, C1-Inh and HK 
present in their native form (105 kDa for C1-Inh and 110 kDa for 
HK). Mr = Relative mobility of protein markers. 
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 AO affected the face in all cases, and the extremities 
(hands, feet and upper limbs) in 7 cases. Eight patients 
also suffered from recurrent abdominal pain. Oral and/
or laryngeal areas were affected at least once in 10 cases. 
The duration of attacks exceeded 24 h in 75% of the cases. 
The most frequent trigger factors were infections, trau-
ma (including pressure), nonsteroidal anti-inflammato-
ry drugs and psychological stress. Two patients reported 
skin bruising following attacks. Four patients had needed 
admission to hospital, 2 of these to an intensive care unit 
as the larynx was affected. Mean age at onset of symp-
toms was 25 years (range 14–37 years). The mean time-lag 
between introduction of the contraceptive and onset of 
symptoms was 2.6 years. Symptoms occurred as soon as 
the first contraceptive was introduced in 9 cases and up 
to a maximum of 16 years afterwards. Interestingly, they 
were already present 3 years before contraception began 
in 1 patient.
 Eleven patients (73%) developed wheals suggestive of 
urticaria. Three had had acute urticaria, 7 had RU and 1 
had CU. For the 7 cases of RU, the frequency of episodes 
was quarterly (n = 1), monthly (n = 3) and weekly (n = 3). 
a b
a
b c
 Fig. 2.  a AO of the lower part of the face in 
a patient on oestrogen contraceptives with 
C1-Inh function deficiency.  b Urticarial 
plaque in the same patient. 
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 Fig. 3. Asynchronous urticaria on the up-
per back ( a ), bilateral, erythematous, pal-
pebral AO ( b ) and lower lip AO ( c ) in a pa-
tient on oestrogen contraceptives with C1-
Inh function deficiency. 
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For the 8 cases of RU or CU ( figs. 2 ,  3 ), the episodes of 
urticaria occurred concomitantly with AO, exclusively in 
2 cases, and sometimes independently in the others. Ur-
ticaria was always pruriginous, but also painful in 2 pa-
tients. 
 Upon discontinuation of contraception, AO resolved 
completely in 6 cases ( table 1 ). The frequency of episodes 
decreased in 7 other cases and there was no improvement 
in 2 cases. RU/CU disappeared in 2 patients (but 1 of 
them still had AO), and persisted in the remaining 6 (it 
remained unchanged in 2) and 5 of them also had recur-
rent AO.
 An association of RU/CU or AO with contraceptives 
was not found in the control population.
 Biological Analyses  
 Proteolytic Cleavage of C1-Inh and HK during and af-
ter Oestrogen Intake. Western blotting of samples with 
antibodies to C1-Inh and to the L-chain of HK showed 
the cleavage of both proteins during oestrogen intake, 
and their return to native forms after withdrawal in 10 
cases with available plasma ( table 1 ). This is exemplified 
in  figure 1 with findings from patient No. 12, who com-
pletely recovered. During oestrogen intake, the extent of 
HK cleavage was comparable to that obtained in a dex-
tran-sulphate-activated control sample ( fig. 1 , ‘activated’ 
lane). 
 Enzymatic Activities. The results are collected in  ta-
ble 1 . At the time of diagnosis, 9 patients developed high 
plasma kininogenase (amidase) activity (in 10 avail-
able blood samples). Plasma kininogenase activity was 
controlled 3–6 months after the discontinuation of con-
traception in 8 of these 9 patients and returned to nor-
mal values in 7. The results from 3 out of 4 patients suf-
fering from both AO and urticaria, for whom we had 
plasma samples before and after oestrogen discontinu-
ation, normalized when contraception was discontin-
ued. Amidase activity was normal in 10 out of 11 pa-
tients with available plasma after the discontinuation of 
oestrogen, independently of the disappearance or per-
sistence of symptoms. In the remaining patient, with an 
only slightly elevated kininogenase level, AO and urti-
caria were improved but still present.
 Bradykinin Catabolism. The activity of all 3 kininases 
was within normal limits for the patients for whom it was 
assessed before and after the discontinuation of contra-
ception.
 Genetic Analysis.  An  F12 gene mutation was absent in 
the 5 patients who were genotyped ( table 1 ).
 Discussion 
 This study supports that AO precipitated by oestrogen 
contraceptives is mediated by BK. It shows that extensive 
proteolysis of HK (as well as C1-Inh) develops in the con-
text of oestrogen intake and high plasma amidase activ-
ity, presumably resulting in the generation of BK, and dis-
appears after the withdrawal of oestrogen and the resto-
ration of native HK and C1-Inh species. Urticaria was 
present in 11/15 patients in this series of women suffering 
from oestrogen-induced BK-AO. Even if 3 cases of acute 
urticaria would be considered as purely coincidental, RU 
or CU was present in 8 women, i.e. 53% of the population 
studied. This prevalence of RU/CU is probably higher 
than in the general population  [20, 21] , especially taking 
into consideration the short period of evaluation (27 
months). The association of RU/CU with oestroprogesta-
tive contraceptives was not found in the control popula-
tion. In addition, to the best of our knowledge, RU/CU is 
not a known adverse effect of oestrogenic contraceptives 
reported in pharmacovigilance studies  [22–24] . So de-
spite the limitations of our retrospective study, we con-
sider that the association of RU/CU with BK-AO is not 
just a coincidence in the context of oestrogenic contra-
ception. 
 The absence of urticaria in the setting of BK-AO is a 
dogma  [25] . It is therefore very difficult to assess whether 
there might be RU/CU in such patients in the literature 
as urticaria is generally an exclusion criterion when a se-
ries of BK-AO patients is constituted  [12, 24–26] . How-
ever, an association between urticaria and likely BK-AO 
has already been reported in a population very similar to 
the population presented here. André et al.  [11]  reported 
a series of 26 women with AO and urticaria (n = 24) or 
urticaria only (n = 2) initially attributed to food allergy. 
All these female patients were in fact taking oral contra-
ception (ethinyloestradiol 35   g and cyproterone acetate 
2 mg in 11 cases) and had a slightly decreased C1-Inh 
function. Discontinuation of contraception in 22 patients 
led to the normalization of C1-Inh function with resolu-
tion of the symptoms in 11 patients, an improvement in 
9 and no change in 2. Other similar but sporadic cases 
have been reported  [27–29] .
 We believe that the association between RU/CU and 
BK-AO has probably been underestimated. The chrono-
logical association of both manifestations occurring si-
multaneously during an attack, and their evolution (either 
recession or persistence of symptoms after the discontinu-
ation of contraception) supports this hypothesis. Such ur-
ticarial lesions might be akin to transient reticulate rashes 
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described in hereditary BK-AO types I and II, occurring 
before bouts of AO  [3] . However, the pathophysiology of 
such phenomena remains to be determined. Mechanisti-
cally, it can be envisaged that AO-BK may develop when 
mast cells are activated, with resulting urticaria, and/or 
that urticaria may develop because mast cells are chal-
lenged when BK is released. The hypothesis of mast cell 
activation by anaphylatoxins in the context of BK-AO, re-
sulting in the production of inflammatory mediators from 
granules, including histamine, might explain the associa-
tion between BK-AO and RU/CU. High plasma proteo-
lytic activity develops in BK-AO type III and in various 
situations of BK-AO triggered by oestrogens  [16] . The 
range of protease substrates is not limited to plasma HK. 
The C1-Inh cleavage observed in our study as well as the 
development of a convertase with anaphylatoxin produc-
tion as shown by Di Scipio and Hugli  [30] are convincing 
demonstrations. Finally, though anaphylatoxins are rap-
idly inactivated by carboxypeptidase N, the long-life C5a-
 des Arg peptide is of sufficient affinity to mast cell C5a 
receptor for subsequent activation  [31] . In addition, it has 
been shown that mast cells may precipitate AO-BK via 
heparin-initiated BK formation  [32] . Alternatively, wheth-
er BK itself may bind the BK-B2 receptor on the mast cell 
and trigger degranulation remains to be demonstrated.
 This study also provides additional insights into the 
natural history of oestrogen-induced BK-AO. The physi-
cians should remember that the time interval between the 
initiation of oestrogen contraception and the occurrence 
of BK-AO is highly variable (from weeks to years), as is 
the case for other iatrogenic triggers like angiotensin-I-
converting enzyme antagonists. The existence of 1 case 
of AO 3 years before contraception began and the persis-
tence of AO in 9 cases out of 15 after the discontinuation 
of contraception, together with the disappearance of ab-
normalities of kinogenase activity in most cases, may 
support the hypothesis of decompensation of a constitu-
tional abnormality of BK production upon introduction 
of contraception. The well-established oestrogen depen-
dency of hereditary AO types III and I/II strengthens this 
hypothesis  [12, 25] , but it is unclear whether some BK-AO 
precipitated by oestrogens could actually be AO type III 
independent of  F12 mutation. In addition, kininase activ-
ity profiles and extension of HK cleavage should be inves-
tigated further in order to unmask any correlation with 
the clinical presentation and evolution.
 In conclusion, we showed here that AO precipitated by 
oestrogen contraceptives is linked to HK cleavage and is 
thus presumably BK-mediated. The presence of RU/CU 
must not rule out the diagnosis of BK-AO in this situation 
when there is a suggestive history. The impact of sus-
tained kinin formation and proteolytic capacity on the 
indirect histamine release by mast cells in female patients 
with BK-AO should be investigated in order to provide an 
etiopathogenic explanation for our observations. Wheth-
er our findings might be generalized to all BK-AO re-
mains also to be investigated. For clinical practice, to de-
tect a mild and transient decrease in C1-Inh function is 
an easy way to link sporadic BK-AO occurring in a wom-
an to oestrogen contraception.
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